お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
950336

コンパニオン診断の世界市場 (~2025年):PCR・ NGS・ISH・IHC

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 320 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
コンパニオン診断の世界市場 (~2025年):PCR・ NGS・ISH・IHC
出版日: 2020年07月02日
発行: MarketsandMarkets
ページ情報: 英文 320 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のコンパニオン診断の市場は予測期間中12.9%のCAGRで推移し、2020年の37億米ドルから、2025年には68億米ドルの規模に成長すると予測されています。コンパニオン診断による各種メリット、標的治療へのニーズの高まり、個別化医療の重要性の拡大などの要因が同市場の成長を推進する見通しです。また、癌の発症率の世界的増加、適用範囲の拡大、次世代シーケンシングへの需要、医薬品開発における重要性、臨床試験数の増加などの要因も参入事業者に成長の機会を示す見通しです。しかし一方で、高コスト性、償還シナリオの不確実性などの課題が市場のさらなる成長の妨げとなる見通しです。地域別で見ると、アジア太平洋地域が予測期間中、最大の成長を示す見通しです。癌の発生率の高さ、プロテオミクス・ゲノミクス研究の増加、研究資金の増加、製薬・バイオテクノロジー企業による投資の拡大、一部の国における個別化治療への注力の拡大などの要因が同地域の成長を推進しています。

当レポートでは、世界のコンパニオン診断の市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、市場規模の推移・予測、製品&サービス・技術・適応症・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題

第6章 産業考察

  • 産業動向
  • 法規制の分析
  • 製品パイプラインの分析

第7章 市場分析・予測:製品・サービス別

  • COVID-19の影響
  • アッセイ・キット・試薬
  • ソフトウェア・サービス

第8章 市場分析・予測:技術別

  • COVID-19の影響
  • ポリメラーゼ連鎖反応(PCR)
  • 次世代シーケンシング(NGS)
  • in situハイブリダイゼーション(ISH)
  • 免疫組織化学(IHC)
  • その他

第9章 市場分析・予測:適応症別

  • COVID-19の影響
    • 乳癌
    • 肺癌
    • 結腸直腸癌
    • メラノーマ
    • 胃癌
  • 感染症
  • 心血管疾患
  • 神経疾患
  • その他

第10章 市場分析・予測:エンドユーザー別

  • COVID-19の影響
  • 医薬品・バイオ医薬品企業
  • リファレンスラボ
  • CRO
  • その他

第11章 市場分析・予測:地域・主要国別

  • COVID-19の影響
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合リーダーシップマッピング
  • ベンダーダイブ
  • 競合状況・動向

第13章 企業プロファイル

  • F. HOFFMANN-LA ROCHE AG
  • AGILENT TECHNOLOGIES, INC.
  • QIAGEN N.V.
  • THERMO FISHER SCIENTIFIC, INC.
  • ABBOTT LABORATORIES, INC.
  • ALMAC GROUP
  • DANAHER CORPORATION
  • ILLUMINA INC.
  • BIOMERIEUX SA
  • MYRIAD GENETICS, INC.
  • SYSMEX CORPORATION
  • ABNOVA CORPORATION
  • GUARDANT HEALTH, INC.
  • ICON PLC
  • BIOGENEX LABORATORIES, INC.
  • 他の有力企業
    • INVIVOSCRIBE TECHNOLOGIES
    • ARCHERDX, INC.
    • NG BIOTECH
    • Q2 SOLUTIONS
    • AMOY DIAGNOSTICS CO., LTD.

第14章 隣接市場・関連市場

第15章 付録

目次
Product Code: MD 5463

"The companion diagnostics market is estimated to grow at a CAGR of 12.9%"

The companion diagnostics market is expected to reach USD 6.8 billion by 2025 from USD 3.7 billion in 2020, at a CAGR of 12.9%. The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

"Cancer segment to witness the highest growth during the forecast period"

The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

"Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user"

The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

"APAC market to witness the highest growth during the forecast period"

Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 40%, Tier 2: 25%, and Tier 3: 35%
  • By Designation - C-level: 33%, Director-level: 41%, and Others: 26%
  • By Region - North America: 38%, Europe: 32%, Asia Pacific: 23%, Latin America: 5%, and the Middle East & Africa: 2%

The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMerieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), Icon Plc (Ireland), and Biogenex Laboratories, Inc. (US)

Research Coverage:

This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
    • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
    • FIGURE 6 MARKET SIZE APPROACH
    • FIGURE 7 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD BILLION)
    • FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2019)
    • FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2019
  • 4.3 REGIONAL MIX: COMPANION DIAGNOSTICS MARKET
    • FIGURE 16 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • 4.4 COMPANION DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES
    • FIGURE 17 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
  • 4.5 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET
    • FIGURE 18 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Advantages of companion diagnostics
      • 5.2.1.2 Growing need for targeted therapy
      • 5.2.1.3 Growing importance of personalized medicine
    • FIGURE 20 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
      • 5.2.1.4 Increasing global incidence of cancer
    • FIGURE 21 GLOBAL CANCER INCIDENCE, 2008-2030
      • 5.2.1.5 Growing application areas of companion diagnostics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of companion diagnostic tests
      • 5.2.2.2 Uncertain reimbursement scenario in different regions
    • TABLE 2 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for next-generation sequencing
    • TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
      • 5.2.3.2 Growing significance of companion diagnostics in drug development
      • 5.2.3.3 Increasing number of clinical trials
    • TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Impact of the COVID-19 pandemic
      • 5.2.4.2 Shortage of trained professionals

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • 6.2.1 IMPACT OF THE COVID-19 PANDEMIC ON THE COMPANION DIAGNOSTICS MARKET
    • FIGURE 22 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
    • 6.2.2 GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS
    • 6.2.3 INCREASING COLLABORATIONS
    • TABLE 5 RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET
  • 6.3 REGULATORY ANALYSIS
    • 6.3.1 NORTH AMERICA
      • 6.3.1.1 US
    • TABLE 6 US: CLASSIFICATION OF MEDICAL DEVICES
    • FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION DIAGNOSTIC PRODUCTS
      • 6.3.1.2 Canada
    • 6.3.2 EUROPE
    • 6.3.3 ASIA PACIFIC
      • 6.3.3.1 Australia
      • 6.3.3.2 Japan
    • TABLE 7 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
      • 6.3.3.3 China
    • TABLE 8 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 6.3.3.4 India
    • FIGURE 24 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 9 INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 6.3.4 BRAZIL
  • 6.4 PRODUCT PIPELINE ANALYSIS
    • TABLE 10 COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS, BY MARKET PLAYER: CURRENT MARKET SCENARIO

7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 11 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 12 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
  • 7.2 IMPACT OF COVID-19 ON THE DEMAND AND SUPPLY OF COMPANION DIAGNOSTIC PRODUCTS & SERVICES
  • 7.3 ASSAYS, KITS, AND REAGENTS
    • 7.3.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT THE ADOPTION OF ASSAYS & KITS
    • TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 14 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
  • 7.4 SOFTWARE & SERVICES
    • 7.4.1 NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES TO CONTRIBUTE TO MARKET GROWTH
    • TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020-2025 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
  • 8.2 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTIC TECHNOLOGY MARKET
  • 8.3 POLYMERASE CHAIN REACTION (PCR)
    • 8.3.1 GROWING APPLICATIONS OF PCR TECHNOLOGIES IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION
    • TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET
    • TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.4 NEXT-GENERATION SEQUENCING (NGS)
    • 8.4.1 NGS SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
    • TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET
    • TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.5 IN SITU HYBRIDIZATION (ISH)
    • 8.5.1 ADVANCEMENTS IN ISH AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET
    • TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.6 IMMUNOHISTOCHEMISTRY (IHC)
    • 8.6.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN CDX TO SUPPORT GROWTH IN THIS SEGMENT
    • TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET
    • TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.7 OTHER TECHNOLOGIES
    • TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2025 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 9.1 INTRODUCTION
    • TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
  • 9.2 IMPACT OF COVID-19 ON VARIOUS INDICATIONS IN THE COMPANION DIAGNOSTICS MARKET
  • 9.3 CANCER
    • FIGURE 25 BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD
    • TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2020-2025 (USD MILLION)
    • 9.3.1 BREAST CANCER
      • 9.3.1.1 Breast cancer is the most common cancer among women-a key factor contributing to the large share of this market segment
    • TABLE 40 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 41 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2020-2025 (USD MILLION)
    • 9.3.2 LUNG CANCER
      • 9.3.2.1 Growing demand for therapeutic drugs and their high efficacy in the treatment of lung cancer to increase CDX adoption
    • FIGURE 26 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
    • TABLE 42 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 43 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2020-2025 (USD MILLION)
    • 9.3.3 COLORECTAL CANCER
      • 9.3.3.1 Growing need for molecular profiling of primary tumors in colorectal cancer to drive growth in this market segment
    • TABLE 44 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 45 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020-2025 (USD MILLION)
    • 9.3.4 MELANOMA
      • 9.3.4.1 Growing incidence of melanoma drives the demand for companion diagnostics
    • TABLE 46 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 47 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2020-2025 (USD MILLION)
    • 9.3.5 GASTRIC CANCER
      • 9.3.5.1 Increasing focus of market players on the development of tests and kits for gastric cancer indications to drive market growth
    • TABLE 48 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 49 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2020-2025 (USD MILLION)
  • 9.4 INFECTIOUS DISEASES
    • 9.4.1 GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT
    • TABLE 50 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 51 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE GROWTH
    • TABLE 52 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 53 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 9.6 NEUROLOGICAL DISEASES
    • 9.6.1 GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS
    • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 55 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 9.7 OTHER INDICATIONS
    • TABLE 56 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 57 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020-2025 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 58 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 59 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
  • 10.2 IMPACT OF COVID-19 ON THE END USERS IN THE COMPANION DIAGNOSTICS MARKET
  • 10.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 10.3.1 WIDE USAGE OF CDX IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
    • TABLE 60 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 61 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 10.4 REFERENCE LABORATORIES
    • 10.4.1 GROWING INCIDENCE OF AND RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
    • TABLE 62 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 63 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 10.5 CONTRACT RESEARCH ORGANIZATIONS
    • 10.5.1 CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES TO TARGETED THERAPY-RELATED CLINICAL TRIALS
    • TABLE 64 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 65 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2025 (USD MILLION)
  • 10.6 OTHER END USERS
    • TABLE 66 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 67 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2025 (USD MILLION)

11 COMPANION DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • FIGURE 27 GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    • TABLE 68 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017-2019 (USD MILLION)
    • TABLE 69 COMPANION DIAGNOSTICS MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 11.2 IMPACT OF COVID-19 ON VARIOUS REGIONS IN THE COMPANION DIAGNOSTICS MARKET
  • 11.3 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 70 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 71 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 72 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.3.1 US
      • 11.3.1.1 US is the largest market for companion diagnostics in North America
    • TABLE 82 US: KEY MACROINDICATORS
    • TABLE 83 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 84 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 85 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 89 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 90 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 92 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.3.2 CANADA
      • 11.3.2.1 Government initiatives to promote companion diagnostics in various indications to drive market growth in Canada
    • TABLE 93 CANADA: KEY MACROINDICATORS
    • TABLE 94 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 95 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 96 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
  • 11.4 EUROPE
    • TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 105 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 106 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.1 GERMANY
      • 11.4.1.1 Germany is a major market for pharmaceutical and biotechnology products in Europe
    • TABLE 116 GERMANY: KEY MACROINDICATORS
    • TABLE 117 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 118 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 119 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.2 UK
      • 11.4.2.1 Growth in the country's life science industry and increasing research are key factors driving market growth in the UK
    • TABLE 127 UK: KEY MACROINDICATORS
    • TABLE 128 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 129 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 134 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 135 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 136 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 137 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.3 SWITZERLAND
      • 11.4.3.1 Switzerland boasts a strong research-oriented pharma industry, a key factor supporting market growth
    • TABLE 138 SWITZERLAND: KEY MACROINDICATORS
    • TABLE 139 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION) 188
    • 11.4.4 FRANCE
      • 11.4.4.1 Increasing government funding for genomics and personalized therapeutics R&D is driving market growth
    • TABLE 149 FRANCE: KEY MACROINDICATORS
    • TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.5 ITALY
      • 11.4.5.1 Growing disease prevalence has contributed to the demand for better, more powerful therapeutics in Italy
    • TABLE 160 ITALY: KEY MACROINDICATORS
    • TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 170 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.6 SPAIN
      • 11.4.6.1 Medical institutes in Spain are increasingly focusing on cancer biomarker research
    • TABLE 171 SPAIN: KEY MACROINDICATORS
    • TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 180 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 181 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.4.7 REST OF EUROPE
    • TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 190 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 191 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
  • 11.5 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 192 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 193 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 194 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 195 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 196 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 197 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 198 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 199 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 200 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 201 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 202 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 203 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.5.1 JAPAN
      • 11.5.1.1 Japan holds the second largest share of the market in APAC
    • TABLE 204 JAPAN: KEY MACROINDICATORS
    • TABLE 205 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 206 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 207 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 208 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 209 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 210 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 211 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 212 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.5.2 CHINA
      • 11.5.2.1 China is one of the most prominent research markets, worldwide
    • TABLE 215 CHINA: KEY MACROINDICATORS
    • TABLE 216 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 217 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 218 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 219 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 220 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 221 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 222 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 223 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 224 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 225 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.5.3 INDIA
      • 11.5.3.1 Government initiatives to tackle the growing burden of cancer are expected to increase the adoption of CDX in the country
    • TABLE 226 INDIA: KEY MACROINDICATORS
    • TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 234 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 235 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 236 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.5.4 AUSTRALIA
      • 11.5.4.1 Growing geriatric population in Australia has resulted in initiatives to enhance healthcare access and infrastructure
    • TABLE 237 AUSTRALIA: KEY MACROINDICATORS
    • TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 244 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 245 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 246 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 247 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.5.5 REST OF ASIA PACIFIC
    • TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 254 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 255 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 256 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 257 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
  • 11.6 LATIN AMERICA
    • TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 266 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 267 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 268 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 269 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.6.1 BRAZIL
      • 11.6.1.1 Brazil dominates the Latin American companion diagnostics market
    • TABLE 270 BRAZIL: KEY MACROINDICATORS
    • TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 276 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 277 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 278 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 279 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 280 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.6.2 MEXICO
      • 11.6.2.1 Mexico is emerging as a prominent medical tourism hub
    • TABLE 281 MEXICO: KEY MACROINDICATORS
    • TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 286 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 287 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 288 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 289 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 290 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 291 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
    • 11.6.3 REST OF LATIN AMERICA
    • TABLE 292 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 293 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 294 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 295 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 296 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 297 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 298 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 299 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 300 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 301 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)
  • 11.7 MIDDLE EAST & AFRICA
    • 11.7.1 RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA
    • TABLE 302 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2019 (USD MILLION)
    • TABLE 303 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2025 (USD MILLION)
    • TABLE 304 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 305 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 306 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2019 (USD MILLION)
    • TABLE 307 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2025 (USD MILLION)
    • TABLE 308 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 309 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 310 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2019 (USD MILLION)
    • TABLE 311 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
    • FIGURE 30 KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2017 AND MAY 2020
    • TABLE 312 GROWTH STRATEGY MATRIX (2017-2020)
  • 12.2 MARKET SHARE ANALYSIS
    • FIGURE 31 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
  • 12.3 COMPETITIVE LEADERSHIP MAPPING, 2019
  • 12.4 VENDOR INCLUSION CRITERIA
  • 12.5 VENDOR DIVE
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 EMERGING COMPANIES
    • 12.5.4 PERVASIVE PLAYERS
    • FIGURE 32 COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2019
  • 12.6 COMPETITIVE SITUATIONS AND TRENDS
    • FIGURE 33 PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2017 & 2020
    • TABLE 313 PRODUCT LAUNCHES & APPROVALS, 2017-2020
    • 12.6.1 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
    • TABLE 314 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS, 2017-2020
    • 12.6.2 ACQUISITIONS
    • TABLE 315 ACQUISITIONS, 2017-2020
    • TABLE 316 EXPANSIONS, 2017-2020

13 COMPANY PROFILES

  • 13.1 F. HOFFMANN-LA ROCHE AG
    • FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • 13.2 AGILENT TECHNOLOGIES, INC.
    • FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • 13.3 QIAGEN N.V.
    • FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT
  • 13.4 THERMO FISHER SCIENTIFIC, INC.
    • FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • 13.5 ABBOTT LABORATORIES, INC.
    • FIGURE 38 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • 13.6 ALMAC GROUP
  • 13.7 DANAHER CORPORATION
    • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT
  • 13.8 ILLUMINA INC.
    • FIGURE 40 ILLUMINA INC.: COMPANY SNAPSHOT
  • 13.9 BIOMERIEUX SA
    • FIGURE 41 BIOMERIEUX SA: COMPANY SNAPSHOT
  • 13.10 MYRIAD GENETICS, INC.
    • FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
  • 13.11 SYSMEX CORPORATION
    • FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT
  • 13.12 ABNOVA CORPORATION
  • 13.13 GUARDANT HEALTH, INC.
    • FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT
  • 13.14 ICON PLC
    • FIGURE 45 ICON PLC: COMPANY SNAPSHOT
  • 13.15 BIOGENEX LABORATORIES, INC.
  • 13.16 OTHER COMPANIES
    • 13.16.1 INVIVOSCRIBE TECHNOLOGIES
    • 13.16.2 ARCHERDX, INC.
    • 13.16.3 NG BIOTECH
    • 13.16.4 Q² SOLUTIONS
    • 13.16.5 AMOY DIAGNOSTICS CO., LTD.

14 ADJACENT AND RELATED MARKETS CHAPTER

  • 14.1 INTRODUCTION
  • 14.2 MOLECULAR DIAGNOSTICS MARKET
    • 14.2.1 MARKET DEFINITION
    • 14.2.2 LIMITATIONS
    • 14.2.3 MARKET OVERVIEW
  • 14.3 MOLECULAR DIAGNOSTICS MARKET, BY REGION
    • TABLE 317 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • 14.4 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
    • TABLE 318 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
    • 14.4.1 POLYMERASE CHAIN REACTION (PCR)
    • TABLE 319 MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2016-2023 (USD MILLION)
    • 14.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
    • TABLE 320 MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016-2023 (USD MILLION)
    • 14.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
    • TABLE 321 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, BY REGION, 2016-2023 (USD MILLION)
    • 14.4.4 IN SITU HYBRIDIZATION
    • TABLE 322 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2016-2023 (USD MILLION)
    • 14.4.5 DNA MICROARRAY
    • TABLE 323 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2016-2023 (USD MILLION)
    • 14.4.6 OTHER TECHNOLOGIES
    • TABLE 324 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2023 (USD MILLION)
  • 14.5 MOLECULAR DIAGNOSTICS MARKET, BY END USER
    • TABLE 325 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
    • 14.5.1 HOSPITAL & ACADEMIC LABORATORIES
    • TABLE 326 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL & ACADEMIC LABORATORIES, BY REGION, 2016-2023 (USD MILLION)
    • 14.5.2 REFERENCE LABORATORIES
    • TABLE 327 MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2016-2023 (USD MILLION)
    • 14.5.3 OTHER END USERS
    • TABLE 328 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016-2023 (USD MILLION)

15 APPENDIX

  • 15.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 15.2 DISCUSSION GUIDE
  • 15.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4 AVAILABLE CUSTOMIZATIONS
  • 15.5 RELATED REPORTS
  • 15.6 AUTHOR DETAILS 333
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.